Several other equities research analysts also recently weighed in on OSUR. Canaccord Genuity reissued a hold rating and issued a $7.00 price target on shares of OraSure Technologies in a report on Wednesday, August 14th. Zacks Investment Research downgraded OraSure Technologies from a hold rating to a sell rating in a report on Tuesday, July 9th. Three investment analysts have rated the stock with a sell rating and one has issued a hold rating to the company. The stock presently has an average rating of Sell and a consensus target price of $7.00.
OSUR stock traded down $0.01 during trading on Thursday, reaching $7.59. 38,138 shares of the company traded hands, compared to its average volume of 581,639. OraSure Technologies has a 12 month low of $6.35 and a 12 month high of $16.20. The business has a 50 day simple moving average of $7.43 and a 200 day simple moving average of $9.07. The company has a market capitalization of $452.44 million, a price-to-earnings ratio of 15.31, a price-to-earnings-growth ratio of 1.58 and a beta of 1.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.13 and a current ratio of 6.99.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The company had revenue of $38.83 million for the quarter, compared to the consensus estimate of $41.48 million. OraSure Technologies had a return on equity of 7.81% and a net margin of 11.83%. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.07 earnings per share. As a group, research analysts forecast that OraSure Technologies will post 0.37 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of OSUR. Acadian Asset Management LLC acquired a new stake in OraSure Technologies in the second quarter worth about $25,000. Roble Belko & Company Inc purchased a new position in shares of OraSure Technologies in the first quarter worth about $29,000. BSW Wealth Partners purchased a new position in shares of OraSure Technologies in the second quarter worth about $29,000. Parallel Advisors LLC purchased a new position in shares of OraSure Technologies in the first quarter worth about $33,000. Finally, Panagora Asset Management Inc. raised its stake in shares of OraSure Technologies by 34.3% in the second quarter. Panagora Asset Management Inc. now owns 9,851 shares of the medical instruments supplier’s stock worth $91,000 after purchasing an additional 2,514 shares during the last quarter. 94.32% of the stock is owned by institutional investors and hedge funds.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Further Reading: What does a market perform rating mean?
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.